Doublewin Biological Technology Co., Ltd.(expird)
Free supplier Enterprise Certification
- Free
supplier - 4th
years
Free supplier Enterprise Certification
Business Type:Lab/Research institutions
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Lab/Research institutions
CAS NO.82640-04-8
A(1-10)Metric TonA(20-50)Metric Ton
1. Quality
Our company is a professional leading supplier in China in
the pharmaceutical area and every batch of steroid powders have to be
tested by our QC (quality control) before steroids are allowed to sell.
2. Delivery
Mass stock for steroids, so we could be able to pack your powders
within 24 hours after your payment confirmed, and the corresponding
picture of your powders' parcel will be sent to you. The lead time within 15 days.
3. Package
A safe and professional disguised package can be guaranteed.
4. Payment
Bitcoin, MoneyGram, , bank transfers
5. Price
The best prices you're sure to be satisfied with, the more you buy, the more competitive prices you will get.
Pharmaceutical Raw Material White Powder Raloxifene Hydrochloride / Raloxifene HCl CAS 82640-04-8 For Anti Estrogen
Raloxifene Hydrochloride
CAS:82640-04-8
MF:C28H28ClNO4S
MW:510.04
Synonyms:RALOXIFENE HCL;RALOXIFENE HYDROCHLORIDE;ly156758 ;methanone,(6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidin ;KEOXIFENE;KEOXIFENE HYDROCHLORIDE;LY 139481;AKOS 92138
Properties
Melting point:250-253°C
storage temp. -20°C Freezer
solubility DMSO: 28 mg/mL, soluble
Abstract
Raloxifene hydrochloride is a second-generation Selective Estrogen Receptor Modulator (SERM) of the benzothiophene family. This drug is similar in effect to tamoxifen, exhibiting estrogen receptor antagonist (blocking) properties in some tissues while acting as an estrogen receptor agonist (activator) in others.
The main point of variation between these two agents is their tissue selectivity. While raloxifene hydrochloride is a strong anti-estrogen in breast and uterine tissues, it appears to be estrogenic in bone. This allows it to protect bone density, mimicking the beneficial effects of endogenous estradiol. This is quite different from tamoxifen, which is anti-estrogenic in both breast and bone.
In a role that was novel for an anti-estrogen, raloxifene hydrochloride was approved by the FDA for the prevention and treatment of osteoporosis in post-menopausal women. It is also being investigated for several other potential uses, including the treatment and prevention of cardiovascular disease, breast cancer, gynecomastia, prostate cancer, acromegaly, and uterine cancer.
Raloxifene Hydrochloride is used to help prevent and treat thinning of the bones (osteoporosis) only in postmenopausal women.
It works like an estrogen to stop the bone loss that can develop in women after menopause, but it does not increase the bone density as much as daily 0.625 mg doses of conjugated estrogens. Raloxifene Hydrochloride will not treat hot flashes of menopause and may cause hot flashes to occur. Also, Raloxifene Hydrochloride does not stimulate the breast or uterus as estrogen does.
Raloxifene Hydrochloride lowers the blood concentrations of total and low-density lipoprotein (LDL) cholesterol, the bad cholesterols, but it does not increase concentrations of high-density lipoprotein (HDL) cholesterol, the good cholesterol, in your blood.
Raloxifene Hydrochloride is also used to lower chances of having invasive breast cancer in postmenopausal women with osteoporosis or at high risk of having invasive breast cancer .
This medicine is available only with your doctor's prescription.
Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, Raloxifene Hydrochloride is used in certain patients with the following medical conditions:
Breast cancer prevention in high-risk women who have already gone through menopause.
Application
May prevent or treat corticosteroid-induced bone loss. American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents or in whom such therapies are contraindicated.
Reduction in the incidence of invasive breast cancer inpostmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial).
Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established. Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1 Not indicated for reduction in the risk of noninvasive breast cancer.
Usage
1. Amino acid, nutrient
2. Labeled , intended for use as an internal standard for the quantification by GC- or LC-mass
spectrometry.
3. A nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.
Mechanism of Action
Evista (raloxifene hydrochloride) is an estrogen agonist/antagonist, referred to as a selective estrogen receptor modulator (SERM) and belongs to the benzothiophene class of compounds. The biological actions of raloxifene are largely mediated through binding to estrogen receptors.
This binding results in activation of estrogenic pathways in some tissues (agonism) and and the blockade of estrogenic pathways in other tissues (antagonism). The agonistic or antagonistic activity of raloxiffene depends on the extent of recruitment of coactivators and corepressors to estrogen receptor (ER) target gene promotors.
Email:doublewin-eunice@nandrolonesteroid.com
WhatsApp:+86 17683962426
Skype:eunice1998